# NCT03803553 (NCT03803553)

> Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03803553
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Massachusetts General Hospital
- Conditions: Metastatic Colon Cancer; Stage III Colon Cancer
- Interventions: FOLFIRI Protocol; ACTIVE SURVEILLANCE; Nivolumab Protocol; Encorafenib/Binimetinib/Cetuximab Protocol; Trastuzumab + Pertuzumab
- Enrollment: 400
- Primary outcome: Disease-free survival (DFS)
- Primary outcome: Clearance rate of ctDNA

## Indexed commentary on NCT03803553 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03803553